barah payu dara

Breast cancer is the most common cancer in women in most parts of the world. One in eight women will develop breast cancer in her lifetime (National Cancer Institute, USA, 1996).

Statistic showed that 1 in 16 Chinese women, 1 in 16 Indian women and 1 in 28 Malay women will develop breast cancer at some stage in their lives (Lim and Halimah, 2004).

Tamoxifen, classicified as SERM (selective estrogen receptor modulator) prescribed for max 5 years for breast cancer patient n effective pada patient with ER positive.

However, new evidence suggests that endoxifen (4-hydroxy-N-desmethyltamoxifen)found is most responsible for tamoxifen activity . Interestingly, some minor tamoxifen metabolites are potent estrogens and many investigators have suggested that different patterns of metabolism of the compound among patients might go some way to explaining why only approximately 60% of ER positive tumors respond to tamoxifen therapy.